BioCentury
ARTICLE | Clinical News

Oral ifetroban: Phase II started

March 23, 2015 7:00 AM UTC

Cumberland began a double-blind, placebo-controlled Phase II trial to evaluate 200 mg oral Boxaban once daily for 3 days in about 16 patients. Subjects will receive Boxaban prior to and during an aspi...